| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Oncology and Pathology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden;
Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden;
First Department of Surgery, Yamanashi Medical University,Yamanashi, Japan;
§
Department of Health and Human Services, National Cancer Institute, National Institute of Health, Bethesda, MD 20892; and
¶
Epimmune, San Diego, CA 92121
Twenty-two new HLA-A2.1-binding peptides derived from the protooncogene HER2/neu were identified and analyzed for their capacity to elicit peptide and tumor-specific CTL responses. We used peptide-pulsed autologous DC from the ascites of patients with ovarian carcinomas to induce CTL. Of the 22 tested new HER2/neu-derived epitopes that could bind HLA-A2 with high (IC50 < 50 nM) or intermediate (50 nM < IC50 < 500 nM) affinity, we report the recognition by CTL of at least four novel epitopes, including HER2(9435), HER2(9665), HER2(9689), and HER2(10952), and confirm that of the known HER2 (9369) epitope. These epitopes were able to elicit CTL that specifically killed peptide-sensitized target cells and, most importantly, a HER2/neu-transfected cell line and the autologous tumor cells. We also confirm that HER2/neu is overexpressed in several melanoma lines, and as a new finding, report that some of these lines are sensitive to CTL induced by the HER2 (9369), HER2(9435), and HER2(9689) epitopes. Finally, CTL clones specific for HER2 (9369), HER2(9435), and HER2(9689) epitopes were isolated from tumor-specific CTL lines, further demonstrating the immunodominance of these epitopes. These findings broaden the potential application of HER2/neu-based immunotherapy.
This article has been cited by other articles:
|
|
 |
|
  M. Barve, J. Bender, N. Senzer, C. Cunningham, F. A. Greco, D. McCune, R. Steis, H. Khong, D. Richards, J. Stephenson, et al. Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non-Small-Cell Lung Cancer J. Clin. Oncol., September 20, 2008; 26(27): 4418 - 4425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Gritzapis, I. F. Voutsas, E. Lekka, N. Tsavaris, I. Missitzis, P. Sotiropoulou, S. Perez, M. Papamichail, and C. N. Baxevanis Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties J. Immunol., July 1, 2008; 181(1): 146 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Conrad, K. Gebhard, H. Kronig, J. Neudorfer, D. H. Busch, C. Peschel, and H. Bernhard CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4 J. Immunol., June 15, 2008; 180(12): 8135 - 8145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q.-S. Du, Y.-T. Wei, Z.-W. Pang, K.-C. Chou, and R.-B. Huang Predicting the affinity of epitope-peptides with class I MHC molecule HLA-A*0201: an application of amino acid-based peptide prediction Protein Eng. Des. Sel., September 1, 2007; 20(9): 417 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Taylor, D. Hershman, N. Shah, N. Suciu-Foca, D. P. Petrylak, R. Taub, L. Vahdat, B. Cheng, M. Pegram, K. L. Knutson, et al. Augmented HER-2 Specific Immunity during Treatment with Trastuzumab and Chemotherapy Clin. Cancer Res., September 1, 2007; 13(17): 5133 - 5143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Scardino, M. Alimandi, P. Correale, S. G. Smith, R. Bei, H. Firat, M. G. Cusi, O. Faure, S. Graf-Dubois, G. Cencioni, et al. A Polyepitope DNA Vaccine Targeted to Her-2/ErbB-2 Elicits a Broad Range of Human and Murine CTL Effectors to Protect against Tumor Challenge Cancer Res., July 15, 2007; 67(14): 7028 - 7036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Czerniecki, G. K. Koski, U. Koldovsky, S. Xu, P. A. Cohen, R. Mick, H. Nisenbaum, T. Pasha, M. Xu, K. R. Fox, et al. Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion Cancer Res., February 15, 2007; 67(4): 1842 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Singh and Y. Paterson Vaccination Strategy Determines the Emergence and Dominance of CD8+ T-Cell Epitopes in a FVB/N Rat HER-2/neu Mouse Model of Breast Cancer. Cancer Res., August 1, 2006; 66(15): 7748 - 7757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Norell, M. Carlsten, T. Ohlum, K.-J. Malmberg, G. Masucci, K. Schedvins, W. Altermann, D. Handke, D. Atkins, B. Seliger, et al. Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific Immunity. Cancer Res., June 15, 2006; 66(12): 6387 - 6394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Gritzapis, L. G. Mahaira, S. A. Perez, N. T. Cacoullos, M. Papamichail, and C. N. Baxevanis Vaccination with Human HER-2/neu (435-443) CTL Peptide Induces Effective Antitumor Immunity against HER-2/neu-Expressing Tumor Cells In vivo. Cancer Res., May 15, 2006; 66(10): 5452 - 5460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Rohrbach, R. Weth, M. Kursar, A. Sloots, H.-W. Mittrucker, and W. S. Wels Targeted Delivery of the ErbB2/HER2 Tumor Antigen to Professional APCs Results in Effective Antitumor Immunity J. Immunol., May 1, 2005; 174(9): 5481 - 5489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Bondurant, M. D. Crew, A. D. Santin, T. J. O'Brien, and M. J. Cannon Definition of an Immunogenic Region Within the Ovarian Tumor Antigen Stratum Corneum Chymotryptic Enzyme Clin. Cancer Res., May 1, 2005; 11(9): 3446 - 3454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Riemer, M. Klinger, S. Wagner, A. Bernhaus, L. Mazzucchelli, H. Pehamberger, O. Scheiner, C. C. Zielinski, and E. Jensen-Jarolim Generation of Peptide Mimics of the Epitope Recognized by Trastuzumab on the Oncogenic Protein Her-2/neu J. Immunol., July 1, 2004; 173(1): 394 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Doytchinova, V. A. Walshe, N. A. Jones, S. E. Gloster, P. Borrow, and D. R. Flower Coupling In Silico and In Vitro Analysis of Peptide-MHC Binding: A Bioinformatic Approach Enabling Prediction of Superbinding Peptides and Anchorless Epitopes J. Immunol., June 15, 2004; 172(12): 7495 - 7502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ruiz, H. Kobayashi, J. J. Lasarte, J. Prieto, F. Borras-Cuesta, E. Celis, and P. Sarobe Identification and Characterization of a T-Helper Peptide from Carcinoembryonic Antigen Clin. Cancer Res., April 15, 2004; 10(8): 2860 - 2867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kono, E. Sato, H. Naganuma, A. Takahashi, K. Mimura, H. Nukui, and H. Fujii Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes Clin. Cancer Res., April 1, 2004; 10(7): 2538 - 2544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vertuani, A. Sette, J. Sidney, S. Southwood, J. Fikes, E. Keogh, J. A. Lindencrona, G. Ishioka, J. Levitskaya, and R. Kiessling Improved Immunogenicity of an Immunodominant Epitope of the Her-2/neu Protooncogene by Alterations of MHC Contact Residues J. Immunol., March 15, 2004; 172(6): 3501 - 3508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Wolpoe, E. R. Lutz, A. M. Ercolini, S. Murata, S. E. Ivie, E. S. Garrett, L. A. Emens, E. M. Jaffee, and R. T. Reilly HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic Mice J. Immunol., August 15, 2003; 171(4): 2161 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Ko, K. Kawano, J. L. Murray, M. L. Disis, C. L. Efferson, H. M. Kuerer, G. E. Peoples, and C. G. Ioannides Clinical Studies of Vaccines Targeting Breast Cancer Clin. Cancer Res., August 1, 2003; 9(9): 3222 - 3234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Ramakrishna, M. M. Ross, M. Petersson, C. C. Gatlin, C. E. Lyons, C. L. Miller, H. E. Myers, M. McDaniel, L. R. Karns, R. Kiessling, et al. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells Int. Immunol., June 1, 2003; 15(6): 751 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Ercolini, J.-P. H. Machiels, Y. C. Chen, J. E. Slansky, M. Giedlen, R. T. Reilly, and E. M. Jaffee Identification and Characterization of the Immunodominant Rat HER-2/neu MHC Class I Epitope Presented by Spontaneous Mammary Tumors from HER-2/neu-Transgenic Mice J. Immunol., April 15, 2003; 170(8): 4273 - 4280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kono, A. Takahashi, H. Sugai, H. Fujii, A. R. Choudhury, R. Kiessling, and Y. Matsumoto Dendritic Cells Pulsed with HER-2/neu-derived Peptides Can Induce Specific T-Cell Responses in Patients with Gastric Cancer Clin. Cancer Res., November 1, 2002; 8(11): 3394 - 3400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-Y. Sun, R. S. Krouse, S. J. Forman, D. Senitzer, I. Sniecinski, S. Chatterjee, and K. K. Wong Jr. Immunogenicity of a p210BCR-ABL Fusion Domain Candidate DNA Vaccine Targeted to Dendritic Cells by a Recombinant Adeno-associated Virus Vector in Vitro Cancer Res., June 1, 2002; 62(11): 3175 - 3183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Scardino, D.-A. Gross, P. Alves, J. L. Schultze, S. Graff-Dubois, O. Faure, S. Tourdot, S. Chouaib, L. M. Nadler, F. A. Lemonnier, et al. HER-2/neu and hTERT Cryptic Epitopes as Novel Targets for Broad Spectrum Tumor Immunotherapy J. Immunol., June 1, 2002; 168(11): 5900 - 5906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Piechocki, S. A. Pilon, and W.-Z. Wei Complementary Antitumor Immunity Induced by Plasmid DNA Encoding Secreted and Cytoplasmic Human ErbB-2 J. Immunol., September 15, 2001; 167(6): 3367 - 3374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Meyer zum Buschenfelde, J. Metzger, C. Hermann, N. Nicklisch, C. Peschel, and H. Bernhard The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells J. Immunol., August 1, 2001; 167(3): 1712 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Keogh, J. Fikes, S. Southwood, E. Celis, R. Chesnut, and A. Sette Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A*0201-Binding Affinity J. Immunol., July 15, 2001; 167(2): 787 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bonvini, W. G. An, A. Rosolen, P. Nguyen, J. Trepel, A. Garcia de Herreros, M. Dunach, and L. M. Neckers Geldanamycin Abrogates ErbB2 Association with Proteasome-resistant {beta}-Catenin in Melanoma Cells, Increases {beta}-Catenin-E-Cadherin Association, and Decreases {beta}-Catenin-sensitive Transcription Cancer Res., February 1, 2001; 61(4): 1671 - 1677. [Abstract] [Full Text]
|
|
|
|
|
|
R. P. M. Sutmuller, L. R. H. M. Schurmans, L. M. van Duivenvoorde, J. A. Tine, E. I. H. van der Voort, R. E. M. Toes, C. J. M. Melief, M. J. Jager, and R. Offringa Adoptive T Cell Immunotherapy of Human Uveal Melanoma Targeting gp100 J. Immunol., December 15, 2000; 165(12): 7308 - 7315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Berard, P. Blanco, J. Davoust, E.-M. Neidhart-Berard, M. Nouri-Shirazi, N. Taquet, D. Rimoldi, J. C. Cerottini, J. Banchereau, and A. K. Palucka Cross-Priming of Naive CD8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells J. Exp. Med., November 27, 2000; 192(11): 1535 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Mosca, A. C. Hobeika, T. M. Clay, S. K. Nair, E. K. Thomas, M. A. Morse, and H. K. Lyerly A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment Blood, November 15, 2000; 96(10): 3499 - 3504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. W. Anderson, G. E. Peoples, J. L. Murray, M. A. Gillogly, D. M. Gershenson, and C. G. Ioannides Peptide Priming of Cytolytic Activity to HER-2 Epitope 369-377 in Healthy Individuals Clin. Cancer Res., November 1, 2000; 6(11): 4192 - 4200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Meyer zum Buschenfelde, N. Nicklisch, S. Rose-John, C. Peschel, and H. Bernhard Generation of Tumor-Reactive CTL Against the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells Derived from CD34+ Hemopoietic Progenitor Cells J. Immunol., October 1, 2000; 165(7): 4133 - 4140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kobayashi, M. Wood, Y. Song, E. Appella, and E. Celis Defining Promiscuous MHC Class II Helper T-Cell Epitopes for the HER2/neu Tumor Antigen Cancer Res., September 1, 2000; 60(18): 5228 - 5236. [Abstract] [Full Text]
|
|
|
|
|
|
J. Gong, N. Nikrui, D. Chen, S. Koido, Z. Wu, Y. Tanaka, S. Cannistra, D. Avigan, and D. Kufe Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity J. Immunol., August 1, 2000; 165(3): 1705 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. Baxevanis, I. F. Voutsas, O. E. Tsitsilonis, A. D. Gritzapis, R. Sotiriadou, and M. Papamichail Tumor-Specific CD4+ T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor J. Immunol., April 1, 2000; 164(7): 3902 - 3912. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
